$4.5B a year is the target for ON-LABEL use. Extended use would go beyond that. While nobody expects to ever get 100% of the total market, there are also patients who have not been formally diagnosed yet, simply because there has been no treatment/cure for it. Now that there is a treatment, number of patients will tick up.
I was expecting more, it is true. I need to find out why they didn't have a bigger beat on earnings. No BS, they missed my number, and apparently lots of other people's number too based on an 8.65% decline on 4x average daily volume.